Drug intelligence / Profile preview

vancomycin + amoxicillin + doxycycline

Development stage
Unknown
Lead developer
Shaare Zedek Medical Center
Modality
Small Molecules
Administration
Oral
01

Overview

vancomycin + amoxicillin + doxycycline is a triple-antibiotic combination regimen investigated by the Shaare Zedek Medical Center for the treatment of acute severe ulcerative colitis and Crohn's colitis. The therapy aims to induce clinical remission by targeting dysbiosis and manipulating the gut microbiome. In clinical trials, this regimen is administered orally alongside standard corticosteroid therapy. The combination provides broad-spectrum coverage, with vancomycin and amoxicillin targeting bacterial cell wall synthesis and doxycycline (or ciprofloxacin in pediatric cases) targeting protein synthesis, thereby reducing the microbial triggers of intestinal inflammation. This approach is based on the hypothesis that specific bacterial populations contribute to the etiology and exacerbation of inflammatory bowel disease (IBD).

Other names
AB-Shaare Zedek Medical Center-ulcerative colitis-Crohn's colitisShaare Zedek antibiotic cocktailShaare Zedek antibiotic regimen
02

Targets

D-Ala-D-Ala (D-Ala-D-Ala terminus)PBP (Penicillin-binding protein family)Bacterial Ribosome

Beyond the preview

Go deeper on vancomycin + amoxicillin + doxycycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vancomycin + amoxicillin + doxycycline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call